Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

ClinicalTrials.gov ID: NCT00943111

Public ClinicalTrials.gov record NCT00943111. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

Study identification

NCT ID
NCT00943111
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Genzyme, a Sanofi Company
Industry
Enrollment
160 participants

Conditions and interventions

Interventions

  • Eliglustat tartrate Drug
  • Imiglucerase Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2009
Primary completion
Oct 31, 2012
Completion
May 31, 2015
Last update posted
Nov 24, 2016

2009 – 2015

United States locations

U.S. sites
17
U.S. states
12
U.S. cities
16
Facility City State ZIP Site status
Tower Hematology Oncology Medical Group Beverly Hills California
UCSF MS Center San Francisco California
University of Colorado Health Science Center - Aurora Aurora Colorado
Yale University School of Medicine New Haven Connecticut
Northwest Oncology Hematology Associates PA Coral Springs Florida
Emory University Medical Genetics Decatur Georgia
Children's Memorial Hospital Chicago Illinois
University of Iowa Hospitals and Clinics Iowa City Iowa
Albany Medical Center Albany New York
North Shore University Medical Center Manhasset New York 11030
Mount Sinai School of Medicine New York New York
New York University School of Medicine New York New York
Duke University Medical Center Durham North Carolina
Cincinnati Children's Hospital Medical Center Cincinnati Ohio
Children's Hospital of Philadelphia Philadelphia Pennsylvania
University of Pittsburgh Medical Center Pittsburgh Pennsylvania
O and O Alpan LLC Springfield Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00943111, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 24, 2016 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00943111 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →